| Name | Title | Contact Details |
|---|
Whatcom Health Information Network is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brooklyn Manor Home for Adults is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rally® believes in putting health care in the hands of individuals with a seamless experience, providing personalized, data-driven information and recommendations that can help improve outcomes and decrease costs for everyone. Rallys Health Solutions help members set personalized daily goals, gives recommendations, and incentivizes progress with rewards. Rallys Care Solutions make health benefits easy to understand and care easy to find on the computer or the Rally app. More than 20 million consumers currently have access to the Rally platform through payers such as UnitedHealthcare, BlueCross BlueShield of South Carolina, and thousands of employer groups. Across offices in Washington, D.C., San Francisco, Chicago, Minneapolis, Denver, and Las Vegas, Rallyers have dedicated themselves to transforming the health care industry for the better—Together.
Universal-Macomb Ambulance is one of the premiere ambulance transport providers in Southeast Michigan. We offer a broad range of ambulance and transport services while serving a number of public safety agencies in our service area. In addition to the
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.